Aerocrine AB is a clinically based medical technology company that leads the way in the development of devices for monitoring inflammation through the measurement of gaseous markers. The company was founded in 1997 by scientists from the prestigious Karolinska Institute in Sweden and has its headquarters in Solna, the Stockholm aera. The founders were the first to identify nitric oxide (NO) as a marker of inflammation. Today, this strong scientific heritage is supported by an international network of clinical advisors as well as an experienced and efficient management team, which is bringing innovative ideas into clinical practice. Aerocrine holds a comprehensive patent portfolio, including eleven approved patents in the USA, with additional patents pending.
The company is currently marketing two products NIOX® Flex and NIOX MINO®. The first product is marketed worldwide and the second product, which represents a new generation of hand-held devices, has recently been launched in Europe. Both devices measure airway inflammation – the main pathogenic factor in asthma and helps doctors to diagnose, monitor and treat asthma patients more accurately in a range of clinical settings. As anti-inflammatory therapy is the cornerstone of asthma treatment, the introduction of a technique to measure inflammation non-invasively opens up a range of possibilities for the improvement of patient care.
Aerocrine is dedicated to improving the management and care of patients by measuring airborne markers, primarily nitric oxide (NO), which is an effective and reliable method for the diagnosis and control of airway diseases.
Aerocrine is committed to performing at the highest level, providing unique, easy-to-use and tailored products for the monitoring of NO as a marker of inflammation. The company’s focus is now on monitoring systems that will improve patient care in the management of inflammatory disorders in the airways, such as asthma. Asthma is a serious, growing global health problem. Today, no alternative methods exist for the routine measurement of the underlying inflammation in asthma.
A round lot of shares in Aerocrine, whose short name is AERO B, amounts to 500. Aerocrine is a Small Cap company in the Health Care sector . You can find more about Aerocrine here.
Paul de Potocki, to the left, CEO of Aerocrine, is welcomed to the Nordic Exchange, by Anders Ackebo, OMX.
Paul de Potocki wait for the first closed deal in Aerocrine's share.
Paul de Potocki toll the bell to make the first closed deal in the Aerocrine share. The first trade was executed at SEK 30.
The guestbook is being signed.
Representatives from Aerocrine gathered togehter. Aerocrines Advisor Kaupthing Bank has guided the company in the listingprocess.
. You can find more about Aerocrine 
